The Profitability of Health Insurance Companies

whitePaper | September 15, 2022

Entities around the globe are using collaboration solutions to evolve the way they do business. From schools to financial institutions to government agencies, organizations everywhere rely on solutions like the Zoom platform for collaboration and communication.

whitePaper | April 28, 2022

The Wall Street Journal called the hybrid workplace a “Cybersecurity Nightmare,” and characterized it as “a hacker’s dream—a constantly changing mix of office and remote workers, devices that move in and out of the company networks, and security staffs stretched thin.” The Wall Street Journal also briefly called out how organizations gain control over this environment – with strong identity-centric security and zero trust.

whitePaper | January 11, 2020

For the first time, in 2020, we see the focus on the “E” and the “S” of environment, social and governance (ESG) as the leading trend globally, including in the United States, where it traditionally has not received as much attention by boards. Indeed, many of the key global trends for 2020, such as board oversight of human capital management (HCM), can be seen as subsets of ESG.

whitePaper | March 13, 2023

The intensifying impacts of climate change create challenges for the environment, public health, and the economy. President Biden set an ambitious target for the United States to achieve a 50-52 percent reduction in annual greenhouse gas emissions1 from 2005 levels by 2030, and is mobilizing a whole-of-government approach to climate action, capitalizing on major legislative achievements, through policies in the 2024 fiscal year budget that hasten and smooth the transition to a net-zero economy.

whitePaper | December 10, 2019

The Trump administration, members of Congress from both parties, and many states have introduced proposals to combat high drug prices. Too often missing from these reform efforts, however, is a clear understanding of a root cause of the crisis: the suppression of fair market competition through various forms of monopoly. This white paper examines and proposes solutions for the two main ways that monopoly drives up the costs and lowers the quality of prescription drugs: increasing corporate concentration in the pharmaceutical industry, and the monopoly markets for individual drugs created by a deeply flawed and increasingly abused patent and regulatory system.

whitePaper | January 28, 2022

Goals and processes for improving existing technology infrastructure and avoiding the risks associated with outdated systems: a roadmap for IT Modernization within the Federal Government